



BioSapien Inc.
303A College Road East,
Princeton, NJ
Khatija Ali
713-979-7791
kpa@biosapieninc.com

08540

Industry:

BioSapien Inc. is a biotech company developing novel biodegradable implantable products that delivery active pharmaceutical ingredients (APIs) for oncology & anti-inflammatory therapies or indications.

Management:

Executive Leadership

CEO - Khatija Ali, MD. Former CEO of Tiger Force Employment and Alioth Entertainment

Board

Khatija Ali, MD
Furwa Hussain
Joshua Barer

Scientific Advisory Board

Seeking top colorectal surgeon - Team
Seeking expert biomedical engineer with experience in biomaterials

Number of Employees: 2

Finance:

Financing to Date

Convertible note \$100K, Feb 27, 2019

Financing Sought

\$600K by July 1st, 2019
Soft circled: \$280K

Legal:

Corporation: C-Corporation, Delaware August 6, 2018
IP: Mintz Levin, provisional patent filed Dec 21, 2018.

Executive Summary

BioSapien Inc. is a biopharma company utilizing 3D printing techniques to provide clinical solutions for localized utilization.

Company History:

BioSapien founded July 2018. The Company developed its product, filed two provisional patents and conducted unofficial freedom to operate.

Market Opportunity / Unmet Need:

The current treatment for localized GI cancer is IV systemic chemotherapy. The systemic chemotherapy leads to systemic side effects (decreased immunity, increased infection risk, quality of life), lasts 8 weeks with numerous hospital visits (minimum 12) and can be grueling for patients. According to CDC, 22% of GI cancer patient population refuses IV chemotherapy (74,000~ annually). With BioSapien's MedChip, we will provide adjunct cancer treatment for patients with decreased systemic effects and decreased hospital visits (minimum 2 visits). MedChip's IP covers a pipeline of drugs - oncology, hormones, anti-inflammatory, corticosteroids, and opioid based. For the first pipeline, we seek oncology and anti-inflammatory.

Products/Services:

MedChip - biocompatible, biodegradable mesh is infused with API which releases efficiently and constantly. This is a drug-delivery mechanism - existing API's such as 5-FU and other oncology drugs are infused into the mesh and then 3D printed to an efficient and customized size.

Commercial / Technical Milestones:

Previous milestones (last 8 months): Obtained \$28K of initial funding, formed company, filed PCT patent, unofficial FTO. Milestones (next 6 months): In-vitro data for animal studies + IP strengthening. Animal studies in 2019. FDA 2020-2023 Phase 3 NDA. Commercialization in 2024.

Intellectual Property:

Provisional patent filed Dec 21, 2018. Design patent to be filed in April. Unofficial FTO granted.

Competition:

3 companies currently looking to use the same mechanism of long-term drug release using the same polymer PEG despite the recent discoveries of inefficiency. Our polymer shows positive results of efficient drug release in >1mo. IP protection.

Financial Projections (Unaudited):

	2019	2020	2021	2022
Expense	0.6M	3M	6M	11M
Net profit	0	0	0	0